100 guests including local sixth form students attend International Men's Day talks and wellbeing workshop at SBC

We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst.

Stevenage Bioscience Catalyst scoops the Most Successful Science Park (Small) Award at UKSPA40 Anniversary Awards

Congratulations to everyone who took part and for a fantastic and insightful conference from UKSPA, The United Kingdom Science Park Association.

Dr Sally Ann Forsyth OBE, CEO of SBC, said:

Four inspiring female leaders discuss their career journeys for International Women’s Day 2024 at SBC

Over 80 guests from across the biotech industry came to Stevenage Bioscience Catalyst to enjoy talks and networking with female leaders in celebration of International Women’s Day 2024 with the theme of ‘Inspire Inclusion.’

Labour launches Life Sciences Industry Strategy at Stevenage Bioscience Catalyst

Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister, launches Labour’s Life Sciences Strategy at Stevenage Bioscience Catalyst (SBC) and witnessed at first hand how SBC is scaling up scientific research and using the latest technologies to revolutionise future healthcare.

Class of 2023 SBC Catalyser Programme ‘graduate’ with flying colours

Ten startups at the intersection of therapeutics and techbio have celebrated completing Stevenage Bioscience Catalyst’s Catalyser Programme by pitching their ideas and commercialisation strategies to an audience of investors, experts and invited guests.

Lab Hotel at Stevenage Bioscience Catalyst now fully booked

Stevenage Bioscience Catalyst (SBC) has awarded space in its Lab Hotel to start-ups Neobe Therapeutics and Genenet Technology. The Lab Hotel is a unique facility offering free lab and office accommodation for six months.

Inspira Pharmaceuticals joins the Lab Hotel at Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst (SBC) welcomes Inspira Pharmaceuticals to its Lab Hotel, a unique facility offering free lab and office accommodation for six months. The start-ups receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop.

Stevenage Bioscience Catalyst celebrates 10 years of innovation

Stevenage Bioscience Catalyst (SBC) is celebrating 10 years since it opened its doors to life sciences companies.

£900m investment to create one of Europe’s largest life sciences hubs in Stevenage

Stevenage Bioscience Catalyst - developer named for campus expansion.

Free lab and office space available in the Lab Hotel at Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst (SBC) is offering free lab and office accommodation for start-ups – and space is available now. In addition to free accommodation, Lab Hotel occupiers receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop. ​

Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups with opportunity for £10,000 award

Stevenage Bioscience Catalyst (SBC) launches an accelerator programme to give start-ups working on data-enabled drug discovery, genomics and advanced therapies the skills they need to get potential new drugs and therapies to market more quickly.

Report demonstrates Stevenage Bioscience Catalyst’s key role in delivering the economic benefit from leading edge UK life sciences

An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering economic benefit from life sciences research and innovation in the UK.

Biotech start-ups successfully graduate from DATA accelerator programme at Stevenage Bioscience Catalyst

Fifteen start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) programme at Stevenage Bioscience Catalyst (SBC), one of Europe’s most important science parks for life sciences.

Dr Sally Ann Forsyth CEO Stevenage Bioscience Catalyst awarded OBE

Dr Sally Ann Forsyth, CEO of Stevenage Bioscience Catalyst (SBC), thanks her colleagues and collaborators after being honoured in the 2021 New Year Honours list. Sally Ann has been awarded an Officer of the Order of the British Empire (OBE) for services to business and science.

Stevenage Bioscience Catalyst opens the Lab Hotel

Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce the opening of the Lab Hotel, a lab and office facility for early-stage start-ups in the field of advanced therapeutics and drug discovery. Successful companies have access to the Lab Hotel facilities and support free for six months, with the first…

New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst

The report released today by BioBeat showcasing the 30 top female leaders in the UK bioscience sector has named three people from organisations based at Stevenage Bioscience Catalyst (SBC), totalling 10% of the list.

Stevenage Bioscience Catalyst opens Spark Building to support cell and gene scale-up

Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.

Stevenage named High Potential Opportunity zone for cell and gene therapy

The Department for International Trade (DIT) has classified Stevenage, Hertfordshire, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas investment into the…

SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing

Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies.

SBC company ReViral raises $44 million in Series C financing

London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund.

Stevenage Bioscience Catalyst announces Professor Jackie Hunter as new Chair

Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of  Chair in September 2020.